Format

Send to

Choose Destination
Br J Cancer. 2018 Nov;119(11):1421-1427. doi: 10.1038/s41416-018-0225-4. Epub 2018 Nov 13.

Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.

Author information

1
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
2
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
3
Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, ON, Canada.
4
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
5
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. joanne.kotsopoulos@wchospital.ca.
6
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. joanne.kotsopoulos@wchospital.ca.

Abstract

BACKGROUND:

Denosumab inhibits the receptor activator of nuclear factor κB (RANK) pathway and is used to treat osteoporosis. Emerging evidence suggests RANK-blockade may play a role in mammary tumourigenesis. Thus, we undertook a population-based study of denosumab use and breast cancer risk in a large cohort of postmenopausal women.

METHODS:

We included women 67+ years with prior bisphosphonate use who filled a first prescription for denosumab. They were matched on age, date, cumulative prior use of and time since last use of a bisphosphonate to women with no history of denosumab. Cox proportional hazards was used to estimate the hazard ratio (HR) of breast cancer with denosumab use.

RESULTS:

A total of 100,368 women were included in the analysis with 1271 incident breast cancer events. Denosumab use was associated with a 13% decreased breast cancer risk (HR = 0.87; 95% CI 0.76-1.00). There was no relationship between increasing number of denosumab doses and breast cancer risk (P-trend = 0.15).

CONCLUSION:

These findings suggest a potential protective effect of ever denosumab use on breast cancer risk in a cohort of older women previously treated with bisphosphonates.

PMID:
30420611
DOI:
10.1038/s41416-018-0225-4

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center